Form 4: ADMA Biologics Director Sells Over $400K in Company Stock Under Pre-Arranged Plan

ADMA Biologics Director Lawrence P. Guiheen sold 20,000 shares of common stock for approximately $419,200, as disclosed in a recent SEC Form 4 filing, with the transaction executed under a Rule 10b5-1 plan.

Summary

• Lawrence P. Guiheen, a Director of ADMA Biologics, Inc. (ADMA), reported the sale of 20,000 shares of common stock.
• The transaction occurred on June 9, 2025, at a price of $20.96 per share, totaling $419,200 in proceeds.
• Following the sale, Mr. Guiheen directly beneficially owns 94,830 shares of common stock, which includes 10,889 restricted stock units granted on February 19, 2025.
• The restricted stock units are set to vest in two equal installments on the sixand 12-month anniversaries of the grant date, subject to continued service.
• Additionally, Mr. Guiheen indirectly beneficially owns 50,990 shares of common stock held in the Lawrence P Guiheen Irrevocable Trust 1.
• The transaction was made pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the transaction was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily a reaction to new negative information. The filing itself is purely transactional and provides no operational or financial performance data.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-arranged sale designed to comply with insider trading regulations and potentially for personal financial planning, rather than a reaction to immediate company news.

Negatives

• The sale of 20,000 shares by a director could be perceived by some investors as a lack of confidence in the company's near-term prospects, despite being pre-planned.

Future Outlook

N/A. This Form 4 filing reports a past transaction and does not provide forward-looking statements or guidance regarding the company's future performance.

Industry Context

N/A. This Form 4 filing details an individual insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe the director's sale and interpret it in various ways, potentially influencing their perception of the stock, though the 10b5-1 plan mitigates immediate concerns.

Next Steps

• Vesting of 10,889 restricted stock units in two equal installments on the sixand 12-month anniversaries of the February 19, 2025 grant date, subject to continued service.

Key Dates

Keywords

ADMA Biologics, ADMA, Form 4, insider trading, stock sale, director, Lawrence P. Guiheen, common stock, Rule 10b5-1 plan, beneficial ownership